other than this............not 100% sure of details
Pipeline
Commercial Milestones
During FY20 Patrys was pleased to announce a fully underwritten, non-renounceable Rights Issue to raise approximately
A$4.29 million before costs. The proceeds raised will be applied to a series of value crystallising stages including; stable
cell line development; toxicology studies and filing for a clinical trial in late 2021 and early 2022. Proceeds of the Rights
Issue will also be used to support development of PAT-DX1-NP and other formats of the antibody, fund operations, the
cost of the issue, working capital, and other business development and corporate activities.
Path ahead
Initiation of non-GLP toxicology and pharmacokinetic studies Q3 2020
Expansion of Deoxymab platform applications (eg. nanoparticles) Q3 2020
Completion of stable cell line development Q4 2020
Initiation of GMP production and formulation program Q1 2021
Initiation of GLP toxicology studies H1 2021
IND (as Australian HREA) submission H2 2021/H1 2022
Scientific publications Ongoing
New IP filings and patent grants Ongoing
Alliances and collaborations Ongoing
Patrys is working hard to give people diagnosed with cancer more targeted treatment options. Our initial focus is on
Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC), with plans to expand into other solid tumors in future.
CY20 CY21
2Q 3Q 4Q 1H 2H
Additional animal models
PK and Non-GLP toxicology
Additional animal models
Non-GLP toxicology and PK
Expression and purification, including full IgG
(PAT-DX3)
GMP productions and
formulation
GLP toxicology
File IND
(Aust HREA)
Grant-funded
studies
Complete cell line
development
IND-enabling
activities for
PAT-DX1
Conjugation
approach
PAT-DX1-NP
9
Intellectual property
Patrys holds a central position in the cell penetrating antibody IP landscape with a wide portfolio of patents and patent
applications covering both the composition of matter and application of Deoxymabs in multiple fields including cancer. The
first patent in the 3E10 portfolio was granted in the US in July 2017 and further patents were granted in Japan and China in
July 2018. The most recent patent in the Deoxymab portfolio was granted in Europe in July 2019 and covers methods of using
Patrys’ novel Deoxymab 3E10 technology, including Patrys’ lead candidate (PAT-DX1), as treatment for a broad range of cancers
and malignancies including gliomas, metastases, breast, pancreatic, ovarian and prostate cancers. Patrys continues to focus on
maintaining patent protection in major jurisdictions where future regulatory approvals and product sales are targeted, with 19
pending patent applications across 10 patent families.
“Patrys remains focused on building and maintaining
patent protection across key jurisdictions. Patrys has
secured patent protection in some of the world’s largest
pharmaceutical markets including USA, Europe, China
and Japan, Patrys is well positioned to preserve future
product sales in key target markets.”
- Patrys CEO and MD, Dr James Campbell
Patrys’ Deoxymab patent portfolio1 Deoxymab patent portfolio
Active intellectual property strategy in place to protect key assets
IP protection granted IP protection pending
Active patent
families
Granted patents2
Patent
applications
pending
https://www.patrys.com/site/market-announcements/2020/623%20Business%20Review%20-%2030%20June%202020_27%20August%202020.pdf